Texas’ CPRIT Injects $1.2m into Texas Tech’s Research Effort Involving GD2 & Neuroblastoma

Texas’ CPRIT Injects $1.2m into Texas Tech’s Research Effort Involving GD2 & Neuroblastoma

C. Patrick Reynolds, MD, PhD, director for the School of Medicine Cancer Center, Texas Tech University Health Sciences Center (TTUHSC) has received nearly $1.2 million from the Cancer Prevention and Research Institute (CPRIT) to support a study titled “GD2 Expression and Response to Chemoimmunotherapy in Neuroblastoma.”

The Health Problem: Neuroblastoma

Neuroblastoma is the most common cancer outside of the brain in infants and young children and is a challenge to treat, especially in patients that relapse after initial therapy. A type of cancer that forms in certain type of nerve tissue, the disease most frequently starts from one of the adrenal glands but may develop in the neck, chest, abdomen or spine.

Current treatments involve surgery, radiation, chemotherapy and stem cell transplantation. Neuroblastoma is a malignancy of early childhood, affecting ≈1 in 7000 children. It is the most common extracranial solid tumor that occurs in children, with an overall incidence rate in the United States of ≈9.7 per million children under the age of 15 years. There is a modest difference in incidence rates by sex (boy: girl rate ratio = 1.2). The highest incidence ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee